|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
Australia Square 264 George Street,Sydney,NSW,AU
|
|
Immutep is a globally active biotechnology company, listed on the Australian Stock Exchange and on the NASDAQ Global Market in the US. As a leader in personalized bio-therapeutic products for cancer, Immutep is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders.
Immutep's main pipeline of products is based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response. The most clinically advanced product is a T cell immunostimulatory factor (APC activator), IMP321, for cancer chemoimmunotherapy which has completed early Phase II trials. A number of additional LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.
|
Immutep Limited Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Immutep Limited email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Immutep Limited customer service number in your country click here to find.
Marc Voigt is the CEO of Immutep Limited. To contact Marc Voigt email at [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.